Aegis Capital initiated coverage of IntelGenx (OTCQX:IGXT) with a “buy” rating and $3 price target. The stock closed at 88 cents on Jan. 26.Read More
Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.
Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served as CFO for Viacell, a stem cell company purchased by PerkinElmer.Read More